Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Good ol’ Thtx

<< Previous

Bullboard Posts

Next >>

Comment by Bucknelly21on Sep 28, 2021 12:15pm

69 Views

Post# 33930844

RE:RE:RE:RE:RE:RE:Good ol’ Thtx

Well past the long period of nothing…

jeffm34 wrote:

Which is why no one here is expecting comment on efficacy. Comment on enrollment numbers however would give a good indication on what dosage they are likely at. If they are above the equivalent dose of docetaxel alone then that is positive. I guess you did need it explained

qwerty22 wrote:

It can equally be the exact opposite to this. Cydy are presently screaming and shouting about an efficacy signal. Problem is it's a measure that is totally meaningless, meanwhile they are saying nothing on what should be the important metrics. Sometimes noise is just there to distract from the sh@tstorm happening elsewhere.

I think people are forgetting how biotech works, it's long periods of nothing with short periods of something. That's how it's always been.

ANALIAS00 wrote: Ask yourself why they did not take that opportunity.

I read from someone that each day that passed without hearing from the ongoing trial is good sign. It was probably true for the first 2 or 3 months but not anymore. I really hope we all get surprised eventually.

They certainly have good ideas about Nash opportunities and their Cancer data so if those cause positive surprise, I would still be VERY interesting to hear from them about the very low insider buying and THtx being sooooo quiet. I am not saying they should be taking risk to over promote, I am just saying that they should, as other said it before, work on creating some sort of anticipation. Specially after the CEO mentionned that SP is ridiculously low.

At this point I like to say that I am 50/50 confident about this investment in THtx. But I keep asking myself why I wont be surprise if this fall ends up to be the beginning of another year of waiting

:o)

jeffm34 wrote:
And it made sense to do it now. They could have easily come out with an update on the trial. Current Enrolment numbers, expected completion dates and expected dates for hard data.

qwerty22 wrote:

The data comes out when it makes sense.

Bucknelly21 wrote: Didn't use there opportunity while they had eyes to generate any excitement about the upcoming data. They just don't seem to want to adopt the retail investor